Despite potential side effects, two drugs make a comeback

Bjorn, Genevive

doi:10.1038/nm0308-226b

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To explain this logic, we breakdown the trials process. Phase‐0 (not a mandatory step, but becoming increasingly common in cancer research) is designed to validate that the intended target can be hit or that a drug can enter the blood stream in humans at low dose [314] . Phase‐I usually focuses on gross tolerance/side effects and pharmacokinetics/pharmacodynamics.…”

Section: Choice Of Compounds To Be Evaluated In Rapid Screening Clinical Trialsmentioning

confidence: 99%

Science's Response to CoVID‐19

Long

Aye

2021

ChemMedChem

View full text Add to dashboard Cite

CoVID‐19 is a multi‐symptomatic disease which has made a global impact due to its ability to spread rapidly, and its relatively high mortality rate. Beyond the heroic efforts to develop vaccines, which we do not discuss herein, the response of scientists and clinicians to this complex problem has reflected the need to detect CoVID‐19 rapidly, to diagnose patients likely to show adverse symptoms, and to treat severe and critical CoVID‐19. Here we aim to encapsulate these varied and sometimes conflicting approaches and the resulting data in terms of chemistry and biology. In the process we highlight emerging concepts, and potential future applications that may arise out of this immense effort.

show abstract

Section: Choice Of Compounds To Be Evaluated In Rapid Screening Clinical Trialsmentioning

confidence: 99%

Science's Response to CoVID‐19

Long

Aye

2021

ChemMedChem

View full text Add to dashboard Cite

show abstract

“…Failure beyond this point indicates, in many instances, more about the application of the drug in a specific context, or contexts. In this way, looking at candidates that have entered Phase-II trials (incidentally, where the majority of drugs fail) and above (and even those withdrawn if not due to adverse side effects, or with manageable contraindications) 314 can help to broaden the scope of screening programs. Such experiments can be performed with knowledge of toxicity and having ideas about, e.g., tolerated doses, pharmacokinetics, in humans.…”

Section: Targeting Infection and Harnessing Fortuitous Antiviral Effementioning

confidence: 99%

Science’s Response to COVID-19

Aye¹,

Long²

2021

Preprint

View full text Add to dashboard Cite

CoVID-19 is a multi-symptomatic disease which has made a global impact due to its ability to spread rapidly, and its relatively high mortality rate. Beyond the heroic efforts to develop vaccines, which we will not discuss, the response of scientists and clinicians to this complex problem has reflected the need to detect CoVID-19 rapidly, to diagnose patients likely to show adverse symptoms, and to treat severe and critical CoVID-19. Here we aim to encapsulate these varied and sometimes conflicting approaches and the resulting data in terms of chemistry and biology. In the process we highlight emerging concepts, and potential future applications that may arise out of this immense effort.

show abstract